Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Professor Eleanor Stride joins NDORMS as the new Professor of Biomaterials, leading the department’s vision in this area of research.

Eleanor is an internationally recognised researcher in medical engineering with pioneering work in biomaterials and their clinical applications, recognised as one of the 50 most influential women in Engineering in 2016.

Her research interests focus on applying engineering principles to solving clinical problems, specifically in drug delivery systems in engineering and biomedical ultrasonics.

Commenting on her appointment, Professor Stride says:

“I am very excited to join NDORMS and foster the genuine integration of engineering and medical research, maximising the benefits of the co-location with clinical researchers. Engineers have a different approach to problem-solving and that can be very useful for multidisplicinary questions. We are trained to analyse systems and solve problems. For me, solving clinical problems is as worthwhile as it gets."

At NDORMS, Eleanor is particularly keen to develop the concept of engineering delivery systems that actively modify the tissue environment to facilitate therapy.

“I believe there is enormous potential for exploiting the synergies between the work being carried out within the Institute of Biomedical Engineering on drug delivery and minimally invasive therapy, and the pioneering research on musculoskeletal and inflammatory conditions in the Botnar and Kennedy Institutes, at NDORMS”, says Professor Stride.QuoteEleanorStride.jpg

Eleanor and her team will bring together their expertise in the fabrication of agents and devices for stimuli responsive drug delivery with the state of the art models, and analytical and imaging techniques being developed at NDORMS.

The new interdisciplinary research theme she will develop in the department will focus on three key areas initially:

  1. Combining pharmaceutical and mechanostimulatory approaches to promote tissue repair;
  2. Investigating the role of inflammatory response in physically mediated drug delivery;
  3. Engineering systems for modulating tissue hypoxia.

Head of Department Professor Andrew Carr, says: “We are delighted to welcome Eleanor to NDORMS and deliver on our vision for biomaterials research, increasing the department’s capabilities in this relatively new field of research and continuing at the forefront of musculoskeletal research worldwide.”

Professor Stride holds a B.Eng. and Ph.D. from University College London. Following the completion of her PhD in 2005, she was appointed to a lectureship and a Royal Academy of Engineering and EPSRC Research Fellowship and subsequently a Readership in 2010. She joined the Institute of Biomedical Engineering in Oxford in October 2011, where she’s been leading an international multidisciplinary team since. Her work has led to the development of new patented technologies for the preparation of microbubble suspensions for ultrasound imaging and drug delivery and she has set up a spin-out company in this area.

She will hold a joint professorship with the Department of Engineering of the University of Oxford, at their Institute of Biomedical Engineering.

Similar stories

Small mechanical forces in immune cells measured at unprecedented sensitivity

Kennedy Main Research

Oxford researchers have used advanced microscopy techniques to measure previously unseen forces generated by cells during an immune response; a breakthrough for mechanobiology and future advances in health and disease.

NDORMS researchers awarded for Dupuytren research

Awards Hand Kennedy Main

Three NDORMS researchers have received awards from the International Dupuytren Society, a patient organisation that brings together Dupuytren Disease patient societies from across the world.

Hope for rheumatoid arthritis patients who are non-responsive to anti-TNF

Arthritis Kennedy Main

New research published in The Lancet shows that tocilizumab is a more effective treatment than rituximab for rheumatoid arthritis patients with a poor response to anti-tumour necrosis factor (TNF).

A new study maps the expression of innate immune receptors during the course of arthritis

Arthritis Kennedy Main

The research, which was a collaboration with researchers from Oxford University and Queen Mary University of London and published in Journal of Autoimmunity, looked at changes in receptors known as toll-like receptors (TLRs) in arthritis at different stages of disease.

International Women's Day

Department Main

It’s International Women's Day! This year’s theme is #Choosetochallenge. We’re celebrating some of the amazing women at NDORMS, and asking them what changes they’d like to see in medical sciences over the next 100 years.

Patients and carers invited to join new group helping to shape research and treatment of bones, muscles and joints

Main PPI

Oxford’s newest patient partner group, OPEN ARMS launches today to explore the causes, treatment and care for patients with musculoskeletal conditions. Its first three patient partners explain why they are involved and invite other members of the public to join the team.